Effective antivenom is unaffordable, unavailable, or reaches rural victims too late
#00132
Rural snakebite victims in low- and middle-income countries die from envenoming that existing antivenom could treat, because effective products are priced out of reach, commercially withdrawn, absent from remote clinics, or arrived too late — an access, market, and logistics fail
#00137Guarantee the market: pooled procurement, subsidy, prequalification and regional manufacturing
Stabilise antivenom supply with guaranteed-volume pooled procurement, donor/government subsidy, WHO prequalification, and regional manufacturing — so effective, region-matched antivenom stays commercially viable and reaches clinics affordably.
#00136Manufacture heat-stable, freeze-dried antivenom for cold-chain-free rural stocking
Produce and distribute lyophilised (freeze-dried) antivenom with a multi-year ambient shelf life so it can be stocked at rural health posts and remote clinics where refrigeration is unreliable or absent.
#00138Cut time-to-treatment with community education and organised rapid transport
Combine community health education (discouraging traditional-healer delay, teaching safe first aid) with organised volunteer rapid transport — e.g., motorcycle networks — to get envenomed patients to an antivenom-equipped centre within the window that determines survival.